Brokerages Set Integra LifeSciences Holdings Corporation (NASDAQ:IART) Price Target at $18.43

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has been given an average rating of “Reduce” by the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $18.4286.

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Integra LifeSciences in a research report on Saturday, September 27th.

Hedge Funds Weigh In On Integra LifeSciences

Several hedge funds have recently added to or reduced their stakes in the company. Rubric Capital Management LP increased its position in Integra LifeSciences by 58.4% in the second quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company’s stock worth $90,233,000 after purchasing an additional 2,710,262 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Integra LifeSciences by 2,418.7% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,799,944 shares of the life sciences company’s stock worth $39,581,000 after buying an additional 1,728,480 shares during the period. Paradigm Capital Management Inc. NY raised its stake in shares of Integra LifeSciences by 57.5% during the second quarter. Paradigm Capital Management Inc. NY now owns 2,181,500 shares of the life sciences company’s stock worth $26,767,000 after buying an additional 796,300 shares during the last quarter. Access Investment Management LLC acquired a new position in Integra LifeSciences in the second quarter valued at approximately $5,348,000. Finally, Soleus Capital Management L.P. boosted its stake in Integra LifeSciences by 29.4% in the second quarter. Soleus Capital Management L.P. now owns 1,387,818 shares of the life sciences company’s stock valued at $17,029,000 after acquiring an additional 315,614 shares during the last quarter. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

Integra LifeSciences stock opened at $14.80 on Friday. The stock has a 50-day simple moving average of $14.19 and a 200 day simple moving average of $14.55. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -2.27 and a beta of 1.21. The company has a quick ratio of 0.73, a current ratio of 1.23 and a debt-to-equity ratio of 1.18. Integra LifeSciences has a 12-month low of $11.06 and a 12-month high of $27.13.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.02. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The firm had revenue of $415.61 million during the quarter, compared to analysts’ expectations of $395.06 million. During the same quarter last year, the company posted $0.63 EPS. The company’s quarterly revenue was down .6% compared to the same quarter last year. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. On average, research analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.